Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.

Clive Bate, Mourad Tayebi, Mario Salmona, Luisa Diomede, Alun Williams

Research output: Contribution to journalArticle

Abstract

A loss of synapses is characteristic of the early stages of the prion diseases. Here we modelled the synapse damage that occurs in prion diseases by measuring the amount of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cortical or hippocampal neurones incubated with the disease associated isoform of the prion protein (PrP(Sc)), or with the prion-derived peptide PrP82-146. The addition of PrP(Sc) or PrP82-146 caused a dose-dependent reduction in the synaptophysin content of PrP wildtype neurones indicative of synapse damage. They did not affect the synaptophysin content of PrP null neurones. The loss of synaptophysin in PrP wildtype neurones was preceded by the accumulation of PrP82-146 within synapses. Since supplements containing polyunsaturated fatty acids (PUFA) are frequently taken for their perceived health benefits including reported amelioration of neurodegenerative conditions, the effects of some common PUFA on prion-mediated synapse damage were examined. Pre-treatment of cortical or hippocampal neurones with docosahexaenoic (DHA) or eicosapentaenoic acids (EPA) protected neurones against the loss of synaptophysin induced by PrP82-146 or PrP(Sc). This effect of DHA and EPA was selective as they did not alter the loss of synaptophysin induced by a snakevenom neurotoxin. The effects of DHA and EPA were associated with a significant reduction in the amount of FITC-PrP82-146 that accumulated within synapses. Such observations raise the possibility that supplements containing PUFA may protect against the synapse damage and cognitive loss seen during the early stages of prion diseases.

Original languageEnglish
Pages (from-to)203-214
Number of pages12
JournalNeurotoxicity Research
Volume17
Issue number3
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Synaptophysin
Prions
Unsaturated Fatty Acids
Synapses
Neurons
Eicosapentaenoic Acid
Docosahexaenoic Acids
Prion Diseases
Fluorescein-5-isothiocyanate
Neurotoxins
Synaptic Membranes
Insurance Benefits
In Vitro Techniques
Synaptic Transmission
Protein Isoforms
Membrane Proteins
Health
Peptides

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. / Bate, Clive; Tayebi, Mourad; Salmona, Mario; Diomede, Luisa; Williams, Alun.

In: Neurotoxicity Research, Vol. 17, No. 3, 04.2010, p. 203-214.

Research output: Contribution to journalArticle

@article{439e9fae2e0b46aea84d8743f07ae67a,
title = "Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.",
abstract = "A loss of synapses is characteristic of the early stages of the prion diseases. Here we modelled the synapse damage that occurs in prion diseases by measuring the amount of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cortical or hippocampal neurones incubated with the disease associated isoform of the prion protein (PrP(Sc)), or with the prion-derived peptide PrP82-146. The addition of PrP(Sc) or PrP82-146 caused a dose-dependent reduction in the synaptophysin content of PrP wildtype neurones indicative of synapse damage. They did not affect the synaptophysin content of PrP null neurones. The loss of synaptophysin in PrP wildtype neurones was preceded by the accumulation of PrP82-146 within synapses. Since supplements containing polyunsaturated fatty acids (PUFA) are frequently taken for their perceived health benefits including reported amelioration of neurodegenerative conditions, the effects of some common PUFA on prion-mediated synapse damage were examined. Pre-treatment of cortical or hippocampal neurones with docosahexaenoic (DHA) or eicosapentaenoic acids (EPA) protected neurones against the loss of synaptophysin induced by PrP82-146 or PrP(Sc). This effect of DHA and EPA was selective as they did not alter the loss of synaptophysin induced by a snakevenom neurotoxin. The effects of DHA and EPA were associated with a significant reduction in the amount of FITC-PrP82-146 that accumulated within synapses. Such observations raise the possibility that supplements containing PUFA may protect against the synapse damage and cognitive loss seen during the early stages of prion diseases.",
author = "Clive Bate and Mourad Tayebi and Mario Salmona and Luisa Diomede and Alun Williams",
year = "2010",
month = "4",
doi = "10.1007/s12640-009-9093-2",
language = "English",
volume = "17",
pages = "203--214",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.

AU - Bate, Clive

AU - Tayebi, Mourad

AU - Salmona, Mario

AU - Diomede, Luisa

AU - Williams, Alun

PY - 2010/4

Y1 - 2010/4

N2 - A loss of synapses is characteristic of the early stages of the prion diseases. Here we modelled the synapse damage that occurs in prion diseases by measuring the amount of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cortical or hippocampal neurones incubated with the disease associated isoform of the prion protein (PrP(Sc)), or with the prion-derived peptide PrP82-146. The addition of PrP(Sc) or PrP82-146 caused a dose-dependent reduction in the synaptophysin content of PrP wildtype neurones indicative of synapse damage. They did not affect the synaptophysin content of PrP null neurones. The loss of synaptophysin in PrP wildtype neurones was preceded by the accumulation of PrP82-146 within synapses. Since supplements containing polyunsaturated fatty acids (PUFA) are frequently taken for their perceived health benefits including reported amelioration of neurodegenerative conditions, the effects of some common PUFA on prion-mediated synapse damage were examined. Pre-treatment of cortical or hippocampal neurones with docosahexaenoic (DHA) or eicosapentaenoic acids (EPA) protected neurones against the loss of synaptophysin induced by PrP82-146 or PrP(Sc). This effect of DHA and EPA was selective as they did not alter the loss of synaptophysin induced by a snakevenom neurotoxin. The effects of DHA and EPA were associated with a significant reduction in the amount of FITC-PrP82-146 that accumulated within synapses. Such observations raise the possibility that supplements containing PUFA may protect against the synapse damage and cognitive loss seen during the early stages of prion diseases.

AB - A loss of synapses is characteristic of the early stages of the prion diseases. Here we modelled the synapse damage that occurs in prion diseases by measuring the amount of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cortical or hippocampal neurones incubated with the disease associated isoform of the prion protein (PrP(Sc)), or with the prion-derived peptide PrP82-146. The addition of PrP(Sc) or PrP82-146 caused a dose-dependent reduction in the synaptophysin content of PrP wildtype neurones indicative of synapse damage. They did not affect the synaptophysin content of PrP null neurones. The loss of synaptophysin in PrP wildtype neurones was preceded by the accumulation of PrP82-146 within synapses. Since supplements containing polyunsaturated fatty acids (PUFA) are frequently taken for their perceived health benefits including reported amelioration of neurodegenerative conditions, the effects of some common PUFA on prion-mediated synapse damage were examined. Pre-treatment of cortical or hippocampal neurones with docosahexaenoic (DHA) or eicosapentaenoic acids (EPA) protected neurones against the loss of synaptophysin induced by PrP82-146 or PrP(Sc). This effect of DHA and EPA was selective as they did not alter the loss of synaptophysin induced by a snakevenom neurotoxin. The effects of DHA and EPA were associated with a significant reduction in the amount of FITC-PrP82-146 that accumulated within synapses. Such observations raise the possibility that supplements containing PUFA may protect against the synapse damage and cognitive loss seen during the early stages of prion diseases.

UR - http://www.scopus.com/inward/record.url?scp=77949895956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949895956&partnerID=8YFLogxK

U2 - 10.1007/s12640-009-9093-2

DO - 10.1007/s12640-009-9093-2

M3 - Article

C2 - 19644728

AN - SCOPUS:77949895956

VL - 17

SP - 203

EP - 214

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 3

ER -